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Abstract
Primary hyperparathyroidism (PHP) is a benign condition characterised by malignant potential. Even in specialist wards, 5–10% of op-
erations for PHP are unsuccessful. The main reasons seem to be ectopy of the parathyroid gland, numerous adenomas, multiglandular 
parathyroid hyperplasia, and intrathyroid location of the parathyroid. The last three decades have witnessed a rapid progression in 
imaging diagnostics. (Endokrynol Pol 2013; 64 (5): 404–408)
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Streszczenie
Pierwotna nadczynność przytarczyc (PNP) jest chorobą łagodną o złośliwym potencjale. Nawet w ośrodkach specjalistycznych 5–10% 
operacji z powodu pierwotnej nadczynności przytarczyc (PNP) kończy się niepowodzeniem. Główną tego przyczyną wydają się być 
ektopia przytarczyc, obecność mnogich gruczolaków, przerost guzkowy przytarczyc oraz wewnątrztarczycowa lokalizacja przytarczyc. 
Ostatnie trzy dekady przyniosły gwałtowny postęp diagnostyki obrazowej. (Endokrynol Pol 2013; 64 (5): 404–408)
Słowa kluczowe: pierwotna nadczynność przytarczyc, ultrasonografia, scyntygrafia MIBI
Primary hyperparathyroidism (PHP) is a benign con-
dition characterised by malignant potential. If left un-
treated, it will double the risk of developing a cancer of 
the breast, prostate or large intestine. It will also cause 
an increase in heart diseases, hypertensive diseases 
and osteoporosis. Roughly one third of patients with 
primary hyperparathyroidism suffer from nephrolithi-
asis, and most of them complain of a reduction in their 
quality of life. It is important to note that patients with 
a 15 year-long history are seen very rarely, and over 
that time practically never [1].
Why then do surgeons try to avoid operations on 
patients with the disease diagnosed biochemically but 
showing a negative result of imaging examinations? 
Based on experience, lack of disease imaging is not 
a contraindication to operative treatment. On the other 
hand, such patients are often a very grateful subject of 
said management [2]. However, it is widely known that 
the picture of parathyroid glands correlates well with 
the clinical severity of the disease [3].
Even in specialist wards, 5–10% of operations for 
PHP are unsuccessful [4]. The main reasons seem to be 
ectopy of the parathyroid gland, numerous adenomas, 
multiglandular parathyroid hyperplasia, and intrathy-
roid location of the parathyroid [5–8].
The statement of the radiologist J.Doppman in 
1968 that “the only localisation study needed by 
a patient undergoing initial parathyroid surgery is 
to locate an experienced parathyroid surgeon” [9] 
was still valid in 1986 during the conference held by 
the National Institutes of Health on the diagnostics 
of parathyroid glands.
Since that time, a rapid progression of imaging 
diagnostics has taken place. Now it is quite easy to de-
fine a highly accurate location of disease-transformed 
parathyroid glands. The advantages of such accurate 
localisation are obvious.
First of all it is very important to shorten the length 
of the operation and to reduce the number of unsuccess-
ful operations. Also, a limited preparation area allows 
a reduced risk of complications, which shortens the 
time of postoperative care and helps to lower the costs 
of treatment [10–12].
In light of the above, imaging examinations of para-
thyroid glands should be: 
 — highly sensitive
 — highly specific
 — as minimally invasive as possible
 — cost-effective
 — available [13].
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High sensitivity and specificity of the examination 
are closely related to the experience of the examiner. 
It is also important that the requisition form has been 
properly completed, giving full information not only on 
the history but also on laboratory findings. The quality 
of the picture is important too [13–16].
It is definitely true that imaging diagnostics can 
enable the surgeon to perform a minimally invasive 
parathyroidectomy (MIP) in a safe way [1, 17].
An analysis of data from 15 American hospital cen-
tres revealed that the costs of an operation for PHP with 
bilateral neck exploration were $1,773 USD and with 
unilateral neck exploration $1,123 USD including the 
costs of scintigraphy (sestamibi). Total costs including 
the description were $429 USD (examination — $305 
USD, description — $124 USD). Reducing the costs is 
undoubtedly connected to the length of the operation. 
A bilateral exploration takes usually 109.3 ± 29 min., 
and a unilateral 49.29 min. [17–20].
Examinations performed to enable identification 
of disease-transformed parathyroid glands are shown 
in Table I.
One of the most generally available and relatively 
cheap examinations is ultrasonography (USG) [21–23]. 
Unfortunately, the sensitivity of this examination, 
usually 71-80%, is to a great degree dependent on the 
experience of the examiner [24, 25]. So USG can be more 
or less sensitive (30-90%) depending on the experience 
and skill of the examiner [6, 23, 26, 27] (Table II). USG 
does not enable localisation of parathyroid glands 
placed in the mediastinum or in retrotracheal or retro-
oesophageal regions due to acoustic shadows from 
bones or air spaces. On the other hand, the latter region 
can be excellently shown by transoesophageal USG [21, 
26, 28, 29]. Moreover, USG enables better imaging of 
an adenoma located within the thyroid gland [30], in 
spite of the ease with which a thyroid tuberculum can 
be confused with an adenoma.
It is well known that a nodular goitre is detected 
in 6–15% of PHP patients. Generally, PHP is estimated 
to coexist with other thyroid diseases in 18–84% of 
patients [1, 31, 32].
Massive nodular goitres restrict the visualisation 
of structures located backwards of the thyroid gland 
through:
reducing the sound wave,
displacing adjacent structures by mass effect,
overlapping acoustic shadows [33, 34].
If USG is performed by a surgeon (adequately ex-
perienced of course), sensitivity and accuracy of such 
examination are 87% and 88% respectively [10]. If the 
result has been assessed as ‘atypical’ or negative, PTH 
level in jugular vein blood is measured.
The term ‘atypical’ refers to the picture in which 
the examiner:
 — is not able to differentiate an ectopic parathyroid 
gland from a transformed lymph node in jugular 
region;
 — suspects a parathyroid gland as the lesion is only 
partially visualized;
 — is not able to differentiate a hypoechogenic lesion 
from a thyroid tuberculum or a cyst located in pos-
terior part of the neck;
 — has found a bilateral suspicious lesion, ‘atypical’ 
with reference to a parathyroid gland [10].
Therefore, an ‘atypical’ result of a USG examination 
does not mean a negative result.
USG does not seem very useful for the evaluation 
of hyperplastic parathyroid glands [25]. In secondary 
parathyroidism, sensitivity of the examination is 60% 
and specificity 64%. If the lesions are connected with 
more than one parathyroid gland, false diagnoses cover 
nearly 30% of patients [34].
If a parathyroid gland is ectopically located in the 
anterior mediastinum or retro-oesophageal region, 
computed tomography is a great help [35]. Sensitivity 
Table I. Examinations enabling identification of disease-transformed parathyroid glands








— subtraction (thallium technetium)
— ‘washout’ (SPECT)/Tc99m sestamibi
5. PET
1. BAC 
2. Selective arteriography/thyrocervical trunk, internal thoracic artery, 
cervical arteries, superior thyroid arteries 




4. Methylene blue 
5. Histopathological     
examination 
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of this examination can be as high as 92% [36, 37]. How-
ever, it is less sensitive than magnetic resonance (MR), 
and a high percentage of false positive results (up to 
50%) is also involved. For this reason, and also due to 
the necessary contrast, a far better method to examine 
ectopic parathyroid glands seems to be MR, in spite of 
the higher costs [30].
In a CT picture, a parathyroid adenoma can be 
difficult to differentiate from lymph nodes, normal 
vessel structures or an exophytic thyroid tuberculum, 
particularly in patients who have previously undergone 
an operation within the neck [38,39].
The characteristics of non-invasive methods for 
localising transformed parathyroid glands indicate 
that the best of them is isotopic radiodiagnostics, par-
ticularly technet scintigraphy Tc99m sestamibi [15, 17, 
40]. This radiotracer is easily assimilated both by the 
thyroid gland and by the parathyroid. However, it is 
soon washed out from the thyroid, whereas parathy-
roid glands have the ability to store it [41]. Compared 
to scintigraphy based on isotope Thal201, Technet99m 
sestamibi is safer when administered in higher doses 
and has closer affinity with parathyroid tissues. Sen-
sitivity of this examination ranges from 85% to 100%, 
the latter in the case of parathyroid adenoma [42, 43]. 
But Technet99m sestamibi is less useful for diagnosing 
parathyroid hyperplasia as only one gland is identified. 
Advantages and disadvantages of non-invasive meth-
ods used to localise disease-transformed parathyroid 
glands are shown in Table III.
It should be stressed here that MIBI is a function test 
and not an anatomical examination. Therefore a smaller 
gland may reduce its sensitivity [28, 44, 45].
There are three types of technet scintigraphy:
 — monoisotopic and two-stage type — scintigraphic 
pictures are interpreted after 15 minutes and with 
an interval of 2–3 hours; quicker elimination of the 
tracer from the thyroid than from the parathyroid 
plays a role;
 — subtraction bi-isotopic type — the thyroid is first 
examined using e.g. iodine J123 or Tc99m pertech-
net, and the picture is ‘subtracted’ from the one 
obtained upon administration of Technet99m 
sestamibi [46, 47];
 — three-dimensional examinations SPECT (Single 
Photon Emission Computed Tomography) [5, 
38, 48].
Using USG together with Tc99sestamibi enables 
the examiner to obtain higher sensitivity of the picture 
from 10% to even 30% [13]. Statistical analyses have 
revealed that further independent factors affecting the 
accuracy of the two diagnostic tests are body mass in-
dex (BMI) and the size of the thyroid gland [8]. If MIBI 
and USG give a negative result, it is recommended to 
perform MRI or stereoscopic computed tomography 
(4D-CT) [36].
It must be stressed that if a reoperation is neces-
sary in patients with persistent primary hyperpar-
athyroidism, the most sensitive examination (50–88%) 
among non-invasive types will be magnetic resonance 
(MR) [49, 50].
Invasive methods used for diagnosing primary hy-
perparathyroidism are much more sensitive. Selective 
angiography shows 60% sensitivity, and intra-operative 
determination of parathormone in venous blood 80%. If 
both examinations are used, the sensitivity will increase 
to as much as 91–95% [50–52]. These examinations help 
to accurately localise an adenoma (angiography) and 
to identify further adenomas or hyperplasia (PTH in 
venous blood) [51]. Unfortunately, the methods may 
involve dangerous complications, including neurologi-
cal disorders, embolism or renal failure.
Table II. Characteristics of non-invasive methods to localise disease-transformed parathyroid glands
Tabela II. Charakterystyka nieinwazyjnych metod obrazowych w diagnostyce chorobowo zmienionych przytarczyc
Factor Localization method





46–80 64–88 75 90.7
Specificity (%) 80–89 80 88–95 73–82 98.8
Reoperation Sensitivity (%) 40 50–88 50
Falsely positive (%) 15–20 50 18 25 Low
Dependent on examiner’s skill +++ + ++ No No
Exposure to radiation No ++ No + +
Costs + +++ ++++ ++ ++
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Intra-operative determination of parathormone 
(IOPTH) helps the examiner to decide whether it is 
better to extend the operation, or instead to end it, if:
 — a suspicious hyperplastic gland has been removed 
but the hormone level does not go down;
 — an abnormal parathyroid gland has been found 
although not confirmed by imaging examinations 
(in such a case, bilateral exploration of the neck is 
avoided to decrease the risk of complications);
 — the diseased gland is not clearly recognisable (an 
answer is given as to which part of the neck should 
be explored; even a 5% difference can play a deci-
sive role);
 — thin-needle biopsy has been performed to examine 
the tissue in question (bioptate is placed in 1 mL of 
physiological saline; the presence of the parathyroid 
tissue is confirmed if PTH level is higher than 1,500 
pg/mL) [52, 53].
 — In light of the available data, it seems that patients 
with primary hyperparathyroidism should receive 
USG of the neck and scintigraphy MIBI in the first 
place to identify the lesions [54–58]. If any discrep-
ancies occur in the results, MR is recommended. 
Operation should be decided afterwards. Levels of 
parathormone should be monitored throughout the 
operation [59–63].
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